(AVTR) Avantor - Ratings and Ratios

Avantor, Inc. (NYSE:AVTR) is a global provider of critical products and services for the biopharma, healthcare, education, government, advanced technologies, and applied materials sectors. With operations spanning the Americas, Europe, Asia, the Middle East, and Africa, the company specializes in delivering high-purity chemicals, lab supplies, and precision equipment essential for scientific research and production. Its product portfolio includes customized excipients for drug formulation, single-use assemblies for biopharmaceutical manufacturing, and advanced chromatography systems. The company also offers biological safety equipment, such as ultra-low-temperature freezers and peristaltic pumps, critical for maintaining controlled environments in laboratories and production facilities. Avantor’s services extend to onsite lab support, equipment maintenance, and biorepository management, ensuring seamless operations for its clients. Founded in 1904 and headquartered in Radnor, Pennsylvania, Avantor has established itself as a key player in the life sciences tools and services industry.

From a technical perspective, AVTR stock is currently trading at $15.47, slightly below its 20-day SMA of $15.50. The stock has been consolidating, with a 50-day SMA of $16.33 and a 200-day SMA of $21.54, indicating a downtrend over the past year. The average true range (ATR) of 0.71 suggests moderate volatility. On the fundamental side, Avantor’s market cap stands at $10.412 billion, with a P/E ratio of 14.69 and a forward P/E of 14.56, signaling reasonable valuation. The price-to-book ratio of 1.75 and price-to-sales ratio of 1.53 reflect its balance sheet strength and revenue generation capabilities. Return on equity (RoE) of 11.94% highlights its profitability.

3-Month Forecast: Based on and , AVTR is expected to face headwinds in the near term, with the stock likely to range between $14.80 and $16.20. The 20-day SMA of $15.50 may act as resistance, while the 50-day SMA of $16.33 could cap upside momentum. Support levels at $14.80 and $15.00 are critical. The ATR of 0.71 suggests price movements will remain contained. Fundamentally, the company’s strong market position and demand for its products in the biopharma sector could offset macroeconomic challenges. Expect moderate volatility with a potential upside of 5-7% if the stock breaks above $16.33.